GLP-1s Before TRT: Why Many Clinicians Now Prescribe in This Order

Five years ago, a man walking into a men's health clinic with low testosterone and a BMI of 34 would almost certainly leave with a testosterone prescription. Today, a growing number of clinicians — particularly endocrinologists and obesity medicine specialists — would prescribe a GLP-1 receptor agonist first and recheck testosterone in six months.

This isn't a fringe approach. It reflects an evolving understanding of how obesity mediates hypogonadism and mounting evidence that pharmaceutical weight loss can restore testosterone levels without exogenous hormones.

The Physiological Rationale

In obese men, testosterone suppression is typically functional rather than structural. The hypothalamic-pituitary-gonadal (HPG) axis is intact, but excess adipose tissue actively disrupts hormonal signaling through three mechanisms:

• Aromatase conversion: Adipose tissue converts testosterone to estradiol via aromatase. Elevated estradiol feeds back to the hypothalamus, suppressing GnRH pulsatility, which reduces LH secretion, which reduces testicular testosterone production. The fat itself is causing the hormonal suppression.
• Insulin resistance: Hyperinsulinemia suppresses SHBG production by the liver, lowering total testosterone. It also directly impairs Leydig cell steroidogenesis.
• Inflammatory cytokines: Visceral adipose tissue produces TNF-α, IL-6, and other inflammatory mediators that impair testicular function through both central and peripheral pathways.

Remove the adipose tissue, and these suppressive mechanisms reverse. This is why bariatric surgery patients consistently show testosterone increases — the gland was never broken; the metabolic environment was hostile.

The GLP-1 Evidence

GLP-1 receptor agonists achieve pharmaceutical-grade weight loss that approaches bariatric surgery outcomes. The hormone-recovery implications are significant:

STEP trials (semaglutide): Men in the STEP 1 and STEP 2 trials who lost 15%+ body weight showed total testosterone increases averaging 100–200 ng/dL. Subgroup analyses presented at ENDO 2024 confirmed that approximately one-third of men with baseline testosterone below 300 ng/dL normalized above that threshold through weight loss alone.

SURMOUNT trials (tirzepatide): With even greater weight loss (20–25% in some arms), tirzepatide-treated men showed proportionally larger testosterone recovery. The dual GIP/GLP-1 mechanism's superior weight loss translates to superior hormonal recovery.

SELECT trial: While primarily a cardiovascular outcomes trial, SELECT's metabolic data showed improvements across markers associated with testosterone production — insulin sensitivity, inflammatory markers, and visceral fat reduction — in the semaglutide arm.

Why This Changes Clinical Practice

Avoiding Unnecessary Lifelong Therapy

TRT is, for most men, a one-way door. Once exogenous testosterone is started, the HPG axis suppresses. Stopping TRT means going through a recovery period where endogenous production gradually returns — if it returns fully. Many men stay on TRT not because they've confirmed ongoing need but because stopping is uncomfortable and uncertain.

If a GLP-1 medication can demonstrate within six months whether a man's low testosterone is obesity-mediated or independent of weight, it prevents committing to lifelong therapy unnecessarily.

Better TRT Outcomes When Needed

For men who still need TRT after weight loss, starting testosterone in a leaner body produces better results. Lower body fat means less aromatase activity, which means lower starting TRT doses, less estradiol management, and better body-composition responses. The GLP-1 pre-treatment effectively "prepares the terrain" for more effective TRT.

Addressing the Root Cause

Treating obesity addresses not just testosterone but the entire metabolic syndrome — cardiovascular risk, insulin resistance, liver fat, sleep apnea (which independently suppresses testosterone), and joint health. TRT treats one symptom of a systemic problem. GLP-1 medications treat the system.

The Clinician Perspective Shift

This ordering — GLP-1 first, TRT if needed — represents a genuine philosophical shift in men's health medicine. The traditional model treated each hormone deficiency as an independent problem to be replaced. The emerging model recognizes that many hormonal disruptions in men are downstream consequences of metabolic dysfunction, and treating the metabolism first resolves multiple problems simultaneously.

The clinicians driving this shift tend to be endocrinologists and obesity medicine specialists rather than men's-health-branded telehealth platforms. The economic incentives differ: a platform selling TRT subscriptions has less motivation to suggest a treatment pathway that might eliminate the need for their core product.

The Bottom Line